SIOUX FALLS, S.D.– SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB’s financial operations and key supporting functions and will work with the senior management team to drive SAB’s growth.
“We welcome Russell to the SAB team at an exciting time in the company’s growth, as we advance SAB-185 into our first Phase 3 trial, as part of the NIH-sponsored ACTIV-2 trial protocol, based on a promising DSMB interim analysis and continue development of our broad pipeline spanning multiple diseases,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “We expect Russell’s extensive and varied experience managing all aspects of financial reporting and operations at global pharmaceutical companies will be invaluable as we seek to scale our operations, broaden our scope and advance our investigational products.”
Mr. Beyer brings more than 25 years of experience to SAB overseeing financial functions at pharmaceutical and other Fortune 100 firms including AstraZeneca, Teva Pharmaceuticals and HBO. Most recently, he was senior director of financial operations at Teva, managing financial operations for shared services for the Americas. Previously, Mr. Beyer held vice president positions at World Fuel Services Corporation, a major marketer of fuel products, where he helped the CEO manage major operational change. Earlier, Mr. Beyer worked in financial management positions at the Clorox Company, where he was CFO for Latin America; at HBO, where he was vice president for finance and treasurer for Latin America; and at AstraZeneca Pharmaceuticals, where he held positions of increasing responsibility, including managing the merger of Astra and Zeneca in Mexico as country CFO. Mr. Beyer began his career at the Hewlett-Packard Company, where he ultimately served as a country chief financial officer. Mr. Beyer received a BA degree from St. Lawrence University and an MBA from the Simon School of Business at the University of Rochester. He is a Certified Management Accountant.
“I am excited to join the SAB team at this pivotal time, as the company continues to develop a late-stage therapeutic candidate and a promising, robust pipeline,” said Mr. Beyer. “SAB has developed and optimized the technology and established sophisticated infrastructure to produce polyclonal antibody therapeutics at scale. I look forward to working with the team and contributing to the company’s success as we embark on this next stage of the company’s growth.”
On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. The transaction is expected to close in the fourth quarter of 2021. (IANS)
